StockNews.AI
EPIX
StockNews.AI
179 days

ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX

1. EPIX faces a class-action lawsuit alleging securities fraud. Investors may be adversely affected. 2. The suit claims false efficacy claims about masofaniten with enzalutamide. It challenges public statements on drug prospects. 3. The litigation covers December 2023 to October 2024. Affected investors have until March 25, 2025 to act. 4. Levi & Korsinsky lead the case with a strong litigation record. Investor contact details and compensation info are provided.

4m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit highlights alleged misrepresentations that could trigger investor uncertainty. Similar biotech litigation events have historically led to share price declines.

How important is it?

The litigation announcement directly increases legal risk and negative sentiment for EPIX. Such lawsuits can materially impact trading behavior and price in the near term.

Why Short Term?

Legal proceedings typically create near-term volatility until outcomes are clear. Past cases have shown similar immediate market reactions.

Related Companies

NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=130861&wire=4 EPIX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in ESSA Pharma Inc. during the relevant time frame, you have until March 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News